Academic Journal
Small-dose cytokines and their combination with 5-fluorouracil for disseminated renal-cell carcinoma. Preliminary results of randomized trial ; Малые дозы цитокинов и их комбинация с 5-фторурацилом при диссеминированном раке почки. Предварительные результаты рандомизированного исследования
| العنوان: | Small-dose cytokines and their combination with 5-fluorouracil for disseminated renal-cell carcinoma. Preliminary results of randomized trial ; Малые дозы цитокинов и их комбинация с 5-фторурацилом при диссеминированном раке почки. Предварительные результаты рандомизированного исследования |
|---|---|
| المؤلفون: | L. V. Demidov, G. Yu. Kharkevich, I. V. Timofeyev, I. G. Markina, V. B. Matveev, N. A. Vetrova, L. A. Kostyakova, Л. В. Демидов, Г. Ю. Харкевич, И. В. Тимофеев, И. Г. Маркина, В. Б. Матвеев, Н. А. Ветрова, Л. А. Костякова |
| المصدر: | Cancer Urology; Том 2, № 4 (2006); 15-18 ; Онкоурология; Том 2, № 4 (2006); 15-18 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2006-2-4 |
| بيانات النشر: | "PH "ABV-Press"", LLC |
| سنة النشر: | 2006 |
| المجموعة: | Oncourology (E-Journal) / Онкоурология |
| الوصف: | There is no standard care for metastatic renal cell carcinoma (MRCC). High and intermediate IL-2 regimens are difficult to recommend due to their high toxicity. A combination of low-dose cytokines is assumed to be effective and safe in MRCC patients. A prospective randomized study was started in 2003.Methods: The eligibility criteria included histopathologically confirmed MRCC, ECOG PS 0—2, no autoimmune diseases, no brain metastases, and normal organ function. All patients were randomized in three arms: IL-2 alone, 1.5 MIU, iv, t.i.w., weeks 1—3 or IL-2 1.0 MIU, iv, t.i.w., weeks 1—3 plus IFN 5 MIU, sc, t.i.w, weeks 1—3 or biochemotherapy group 5-FU, 500 mg/m 2 , iv, once a week, weeks 1—3 plus IL-2 1.0 MIU, iv, t.i.w., weeks 1—3 plus IFN 5 MIU, sc, t.i.w., weeks 1—3. Cycles were repeated every three weeks. A response was evaluated according to RECIST every 2 cycles.Results: 64 patients were enrolled of whom 63 were analyzed. The patients’ median age was 55.4 years (range 16—74). 55.6% of the patients had a poor prognosis (as described by Motzer et al., 2002). Bone metastases were present in 52.4%. Sixteen patients treated with IL-2 alone showed no CR, no PRs, 2 SDs, and 14 PDs. Of the 23 patients in IL-2+IFN group, 5 PRs, 8 SDs, and 10 PDs were observed, with a response rate of 21.7%. Amongst the 24 patients in 5-FU+IL-2+IFN group, 1 CR, 3 PRs, 10 SDs, and 10 PDs were shown, with a response rate of 16.7%. One-year survival was 20.0%, 81.3% and 81.0%, respectively. Flu-like syndrome was the most common side effect in the patients receiving IFN (89.1%, grade 1, CTC). Hypotension associated with IL-2 (all groups) was seen in 56.3% (grade 1 in 50% and grade 2 in 6.3%). The other toxicities were 12.7% grade 1 neutropenia and vomiting in 4.7% (group 3).Conclusions: Small-dose IL-2 in combination with IFN and 5-FU in MRCC is feasible, tolerable, with the efficacy comparable to other more toxic therapeutic modalities. ; . |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | Russian |
| Relation: | https://oncourology.abvpress.ru/oncur/article/view/1146/1032; Atzpodien J., Kirchner H., Jonas U. et al. Interleukin-2 and interferon-α 2a based immunotharapy in advanced renal cell carcinoma: a prospectively randomized trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004;22:7.; Calugiuri M.A. Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Am J Clin Oncol 1994;17:199.; Gitlitz B., Figlin R. Cytokine-based therapy for metastatic renal cell cancer. Urol Clin North Am 2003;30(3):589–600.; Lissoni P., Barni S., Ardizzoia A. et al. A randomized study of low-dose interleukin-2 plus interferon-alpha first line therapy for metastatic RCC. Tumor 1993;79:397–400.; Margolin K. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27(2): 194–203.; Negrier S., Escudier B., Lasset C. et al. Recombinant human interleukin-2, recombinant interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 1998;338:1272.; https://oncourology.abvpress.ru/oncur/article/view/1146 |
| DOI: | 10.17650/1726-9776-2006-2-4-15-18 |
| الاتاحة: | https://oncourology.abvpress.ru/oncur/article/view/1146 https://doi.org/10.17650/1726-9776-2006-2-4-15-18 |
| Rights: | Authors who publish with this journal agree to the following terms:Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). ; Авторы, публикующие в данном журнале, соглашаются со следующим:Авторы сохраняют за собой авторские права на работу и предоставляют журналу право первой публикации работы на условиях лицензии Creative Commons Attribution License, которая позволяет другим распространять данную работу с обязательным сохранением ссылок на авторов оригинальной работы и оригинальную публикацию в этом журнале.Авторы сохраняют право заключать отдельные контрактные договоронности, касающиеся не-эксклюзивного распространения версии работы в опубликованном здесь виде (например, размещение ее в институтском хранилище, публикацию в книге), со ссылкой на ее оригинальную публикацию в этом журнале.Авторы имеют право размещать их работу в сети Интернет (например в институтском хранилище или персональном сайте) до и во время процесса рассмотрения ее данным журналом, так как это может привести к продуктивному обсуждению и большему количеству ссылок на данную работу (См. The Effect of Open Access). |
| رقم الانضمام: | edsbas.293F8167 |
| قاعدة البيانات: | BASE |
| DOI: | 10.17650/1726-9776-2006-2-4-15-18 |
|---|